PubMed Health⌕ Search

PubMed · 11391937

[Classification of malignant lymphomas].

Abstract

Hodgkin's disease is characterized by malignant tumor in lymphoid tissue, excluding non-Hodgkin's lymphomas and lymphoid leukemias. It can be diagnosed by the characteristic histologic picture, which contains Reed-Sternberg cells. The Rye classification for Hodgkin's disease has been useful to date, however, since non-Hodgkin's lymphomas were first recognized as a distinct group a variety of classifications have been proposed although none are entirely satisfactory. At present, it is concluded that the most practical approach to lymphoma categorization is simply to define the diseases with the currently available morphologic, immunologic, and genetic techniques, and use the REAL and WHO classifications for lymphoid malignancies. It is important to develop more concise and practical classifications in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Murohashi. 2001. [Classification of malignant lymphomas].. https://pubmed.ncbi.nlm.nih.gov/11391937/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗